ArticleNPJ breast cancer2022

Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer.

Sunil Pancholi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.